Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat + rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma
jRCT2041210129Phase 2Active, not recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and rituximab in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Overall response rate. Started May 2022; status: active, not recruiting.
02
Drugs
tucidinostatrituximab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2041210129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210129.